{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-041026","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.297503+00:00","generated_at":"2026-06-02T05:20:57.756336+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024","bullets":["Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.","Cash and short-term investments $58.6M; company believes it can fund operations for at least 12 months.","CMS granted HCPCS code and TDAPA for DefenCath effective July 1, 2024, providing 5 years of additional ESRD reimbursement.","Commercial launch of DefenCath in inpatient setting commenced April 15, 2024; outpatient launch expected July 2024.","Entered 5-year supply contract with ARC Dialysis; FDA meeting on DefenCath in TPN requested, feedback expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-041026","json":"https://secwatch.observer/filing/0001213900-24-041026.json","markdown":"https://secwatch.observer/filing/0001213900-24-041026.md","text":"https://secwatch.observer/filing/0001213900-24-041026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/0001213900-24-041026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/ea020558401-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:20:57.756336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3336fbac30ae79aa6593016d7e7b569c6e001511","claim":"CorMedix Inc. reported first quarter ended March 31, 2024 results: net income net loss of $14.5 million, EPS $0.25 per share.","evidence_excerpt":"CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/0001213900-24-041026-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $14.5 million"},{"label":"EPS","value":"$0.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}